A new cancer drug, Opdivo, is working so well that pharmaceutical giant Bristol-Myers Squibb announced Monday it is stopping a trial in lung cancer two years ahead of schedule. Pasi Janne, professor of medicine at Dana-Farber Cancer Institute, is quoted.
News & Research
